APA (7th ed.) Citation

ND, S., JG, S., BJ, S., KR, K., SK, A., MJ, F., . . . AA, A. (2024). Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas. Blood advances, 8(3), 780. https://doi.org/10.1182/bloodadvances.2023011997

Chicago Style (17th ed.) Citation

ND, Shukla, et al. "Specificity of Immunoglobulin High-throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas." Blood Advances 8, no. 3 (2024): 780. https://doi.org/10.1182/bloodadvances.2023011997.

MLA (9th ed.) Citation

ND, Shukla, et al. "Specificity of Immunoglobulin High-throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas." Blood Advances, vol. 8, no. 3, 2024, p. 780, https://doi.org/10.1182/bloodadvances.2023011997.